More than six decades after chemist Calvin Stevens first synthesized ketamine at Parke-Davis—an endeavor initially aimed at developing a safer, more reliable surgical anesthetic—the molecule has undergone a profound transformation. Once confined to the operating room, this compound has migrated into the heart of modern psychiatry, evolving into a blockbuster therapeutic agent.
At the center of this shift is esketamine, the potent S-enantiomer of the original ketamine molecule. Marketed by Johnson & Johnson under the brand name Spravato, the drug reached a major milestone in January 2025 when U.S. regulators cleared it as the first and only monotherapy for treatment-resistant depression (TRD). Following a cautious market entry, the drug has seen its financial profile soar; annual worldwide sales hit approximately $1.7 billion last year, with market analysts projecting a climb toward $2.3 billion in 2026.
Now, Johnson & Johnson is leveraging new data presented at the Psych Congress Elevate conference to further solidify the drug’s role in the psychiatric toolkit. By focusing on long-term remission rates across six pivotal clinical trials, the company is attempting to shift the narrative from mere "symptom management" to the more ambitious goal of "clinical remission."
A Chronology of a Psychiatric Breakthrough
The journey of esketamine from a laboratory curiosity to a cornerstone of depression treatment has been defined by regulatory milestones and a slow, deliberate expansion of its indications.
- 1960s: Calvin Stevens synthesizes ketamine, establishing a legacy of dissociative anesthesia.
- March 2019: The FDA approves Spravato (esketamine) as a nasal spray for treatment-resistant depression, specifically as an add-on therapy to conventional antidepressants.
- January 2025: Regulatory hurdles are cleared as Spravato receives approval as a monotherapy, allowing clinicians to prescribe it without the mandatory requirement of an oral antidepressant backbone.
- 2025–2026: As adoption grows, the focus shifts toward real-world data and long-term durability of treatment, culminating in the comprehensive review presented by Dr. Rakesh Jain at Psych Congress Elevate.
The clinical necessity for this evolution is stark. According to the National Institute of Mental Health, an estimated 21 million U.S. adults experienced at least one major depressive episode in 2021. Of the 8.9 million adults receiving pharmacological treatment for major depression, roughly one-third—approximately 2.8 million individuals—fail to achieve an adequate response to standard oral antidepressants. This failure to respond serves as the clinical definition of treatment-resistant depression (TRD), a state where patients often face cycles of medication changes with diminishing returns.
Defining the "Elusive Goal": The Remission Analysis
For Dr. Rakesh Jain, a clinical professor of psychiatry at Texas Tech University School of Medicine and the lead author of the recent data analysis, the conversation in psychiatry must move beyond simple response rates.
"There are millions upon millions of patients, some of them your friends and mine, some of them your family members, who are being treated for depression and are simply not in remission," Dr. Jain stated. "The moment you go to a second antidepressant, the remission rate drops sharply, to as little as 14 or 15%. It’s a very sharp drop."
The MADRS Benchmark
The analysis centers on the Montgomery-Åsberg Depression Rating Scale (MADRS), a 10-item clinician-rated instrument. While mild depression is categorized by scores of 7–19 and severe depression by 35+, clinical remission is traditionally defined by a score of 10 or below.
Dr. Jain noted that the research team intentionally "tightened" the criteria in their analysis. "We said, okay, 12 is fine, but can we go to 10? And it performed quite well, even at 10. That’s the key." By holding the drug to a stricter standard, the researchers aimed to prove that Spravato’s efficacy is robust enough to reach the most demanding clinical targets.
Comparative Data vs. Placebo
The data presented at the conference compiled results from six studies, including:
- TRANSFORM-2: Showing Spravato plus an antidepressant achieved a 42.6% remission rate, compared to 24% for the placebo-plus-antidepressant group.
- Monotherapy Trials: Showing 13.9% to 21.5% remission at week four, significantly outperforming placebo at 6.5%.
- Long-term Extension Studies: Tracking patients for up to 5.5 years, with remission rates reported at 49.3% after one year and maintaining 43.2% at the long-term follow-up mark.
While the poster is descriptive—lacking a formal meta-analysis or pooled statistical comparisons—it provides a comprehensive view of how the drug behaves in both controlled, double-blind environments and long-term open-label settings.
Critical Perspectives and Official Responses
Despite the optimism surrounding the data, the clinical community remains divided. The reception of esketamine varies significantly across global health authorities, reflecting the ongoing debate over the drug’s cost-effectiveness and its real-world impact.
The Global Regulatory Spectrum
The 2022 VA/DoD depression guidelines maintain a conservative stance, listing ketamine/esketamine as an "augmentation option" but assigning it a "weak for" recommendation. The guidance cites low-quality evidence and expresses explicit concerns regarding the feasibility of the intensive, supervised delivery model required by the drug’s REMS (Risk Evaluation and Mitigation Strategy) program.
In the United Kingdom, the National Institute for Health and Care Excellence (NICE) declined to recommend esketamine for routine NHS use in 2022, arguing that the economic evidence did not support its cost-effectiveness. Conversely, regulators in Scotland reached a divergent conclusion, highlighting the lack of global consensus on the drug’s value proposition.
The Scientific Debate
Academic journals have provided a platform for both supporters and skeptics. A 2025 editorial in the American Journal of Psychiatry by Dr. Sanjay Mathew and Dr. Nicholas Murphy questioned the duration of treatment, suggesting that the clinical program failed to adequately define how long patients should remain on the drug.
Furthermore, a systematic review published in the same journal by Fountoulakis et al. suggested that esketamine’s effect sizes—ranging from 0.15 to 0.23 during the early weeks—were comparable to those of atypical antipsychotic augmentation. This comparison is particularly relevant, as some clinicians have previously dismissed atypical antipsychotics for their own perceived lack of superiority in TRD.
Implications for Clinical Practice
The most significant hurdle for Spravato is not necessarily the data itself, but the "psychology of the clinician." Psychiatry is a field defined by a high degree of caution and, at times, inertia.
Overcoming Institutional Inertia
Dr. Jain argues that the primary barrier to adoption is a combination of skepticism and a lack of awareness regarding the full scope of available data. "Psychiatry is slow to change, it just is," Jain remarked. "So there are many clinicians who have heard of Spravato but are hesitant, not for any particular reason; that’s just the nature of our field."
The logistics of the drug also present a challenge. Because Spravato is delivered in a restricted setting, it requires:
- Strict Monitoring: Patients must remain in a certified clinic for at least two hours following administration due to risks of sedation and dissociation.
- Safety Protocols: Patients are prohibited from driving until the day after treatment, requiring a significant commitment of time and support.
The Path Forward
Despite these logistical frictions, the feedback from the Psych Congress Elevate attendees suggests a shift. Clinicians who engaged with the data expressed a desire to incorporate esketamine into their treatment algorithms much earlier.
The core takeaway from the J&J presentation is that for the millions of patients currently failing to find relief through standard SSRIs or SNRIs, the threshold for trying more advanced interventions like esketamine is being lowered. By emphasizing durable, long-term remission, J&J is attempting to reframe the conversation from "what to do after multiple failures" to "when is the right time to intervene for better outcomes."
As J&J continues to push for broader adoption, the company’s success will ultimately depend on its ability to demonstrate that the burden of the REMS program is a price worth paying for the life-altering potential of reaching, and holding, clinical remission. For the 2.8 million Americans living with treatment-resistant depression, the answer to that question remains the most critical variable in their path to recovery.
About the Author
